Estimation of the influence of 6 week therapy by meldonium (Mildronate®) at bulbar capillaroscopy indexes in chronic ischemic heart and brain disease female patient


DOI: https://dx.doi.org/10.18565/therapy.2020.3.105-110

Heylo T.S., Danilogorskaya Yu.A., Nazarenko G.B., Martynov A.I.

1 Therapeutic Ophthalmology Center LLC, Moscow; 2 I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russia; 3 A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Healthcare of Russia
Despite achievements in medicine and pharmacotherapy, cardiovascular diseases continue to lead among the death causes almost all over the world. The results of modern studies show that endothelial dysfunction is the first stage in the development of cardiovascular pathology, which leads to changes of vascular wall morphology and blood flow parameters in blood vessels’ lumen at various levels (from arteries to capillaries).
Disorders in the microcirculatory chain are the most important aspect in the pathogenesis of organs and tissues’ function impairment.They could be observed both in isolation and in combination with impaired blood flow in large vessels. The problem of diagnosing microcirculatory disorders and approaches to their pharmacological correction is actual first of all. The article describes the case of use an ophthalmic «OKO» capillarooscope (patent No. 132699 of 2013) for blood flow estimation in the arterioles and venules of the bulbar conjunctiva and limb of the eye in a patient with chronic ischemic diseases of the cardiovascular system and central nervous system before and after meldonium (Mildronate®) treatment at 1000 mg/day dose for 40 days.
Keywords: microcirculation disorder, capillaroscopy, meldonium, endothelial dysfunction, hypertension, atherosclerosis
Read entire article

Literature


  1. Dzerve V., Matisone D., Pozdnyakov Y., Oganov R. Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial. Sem Cardiovasc Med. 2010; 16(3): 1–8.

  2. Дзерве В. Эффективность Милдроната в лечении ишемической болезни сердца: результаты исследования MILSS II. Здоров’я України. 2010; 7: 24–25. [Dzerve V. Efficacy of Mildronat in treatment of coronary heart disease: results of the study MILLS II. Zdorov'e Ukrainy. 2010; 7: 24–25 (In Russ.)].

  3. Dzerve V. MILSS I Study Group. A dose-dependent improvement in exercise tolerance in patients with stable angina treated with Mildronate: a clinical trial «MILSS I». Medicina (Kaunas). 2011; 47(10): 544–51.

  4. Посненкова О.М., Киселев А.Р., Шварц В.А. Влияние терапии препаратом Кардионат на качество жизни у больных острым инфарктом миокарда с подъемом сегмента ST в ранний постинфарктный период. Consilium medicum. 2010; 5: 94–98. [Posnenkova O.M., Kiselev A.R., Shvarts V.A. Impact of Mildronat on quality of life in patients with ST elevation myocardial infarction in early post-infarction period. Consilium medicum. 2010; 5: 94–98 (In Russ.)].

  5. Нечаева Г.И., Поташов Д.А., Желтикова Е.Н. Мельдоний в лечении больных инфарктом миокарда. Кардиология. 2014; 9: 93–96. {Nechaeva G.I., Potashov D.A., Zheltikova E.N. Meldonium in treatment of patients with myocardial infarction. Kardiologiya. 2014; 9: 93–96 (In Russ.)].

  6. Нечаева Г.И., Желтикова Е.Н. Эффекты мельдония в раннем постинфарктном периоде. Кардиология. 2015; 8: 35–42. [Nechaeva G.I., Zheltikova E.N. Effects of meldonium in early postmyocardial infarction period. Kardiologiya. 2015; 8: 35–42 (In Russ.)]. doi: https://dx.doi.org/10.18565/cardio.2015.8.35-42.

  7. Лямина Н.П., Котельникова Е.В., Карпова Э.С. с соавт. Кардиопротективные возможности препарата мельдоний при вторичной профилактике после чрескожных коронарных вмешательств у больных с документированной ишемией миокарда. Кардиология. 2014, 7: 60–65. [Lyamina N.P., Karpova E.S., Kotelnikova E.V. et al. Cardioprotective capabilities of drug meldonium in secondary prevention after percutaneous coronary intervention in patients with documented myocardial ischemia. Kardiologiya. 2014, 7: 60–65 (In Russ.)].

  8. Гордеев И.Г., Лучинкина Е.Е., Хегай С.В. Коррекция дисфункции миокарда у больных стабильной стенокардией, подвергшихся коронарной реваскуляризации, на фоне приема цитопротектора милдроната. Российский кардиологический журнал. 2009; 2: 54–58. [Gordeev I.G., Luchinkina E.E., Hegay S.V. Cytoprotector mildronate in correcting myocardial dysfunction among stable angina patients after coronary revascularization. Rossiyskiy kardiologicheskiy zhurnal. 2009; 2: 54–58 (In Russ.)]. doi: https://doi.org/10.15829/1560-4071-2009-2-54-58.

  9. Карпов Р.С., Кошельская О.А., Врублевский А.В. Клиническая эффективность и безопасность милдроната при лечении хронической сердечной недостаточности у больных ишемической болезнью сердца. Кардиология. 2000; 6: 69–74. [Karpov R.S., Koshelskaya O.A., Vrublevskiy A.V. Clinical efficacy and safety of Mildronat in treatment of chronic heart failure in patients with coronary heart disease. Kardiologiya. 2000; 6: 69–74 (In Russ.)].

  10. Дзерве В. Новые возможности в лечении пациентов с заболеваниями периферических артерий: результаты исследования MI&CI. Лikи Украiни. 2010; 8: 99–101. [Dzerve V. New capabilities in treatment of patients with peripheral artery disease: results of the study MI&CI. Liki Ukrainy. 2010; 8: 99–101 (In Russ.)].

  11. Артюшкова Е.В., Покровский М.В., Артюшкова Е.Б. с соавт. Эндотелио- и кардиопротективные эффекты мельдония и триметазидина при L-NAMEиндуцированной эндотелиальной дисфункции в эксперименте. Курский научно-практический вестник. Человек и его здоровье. 2010; 32: 5–10. [Artyushkova E.V., Pokrovskiy M.V., Artyushkova E.B. et al. Endothelio- and cardioprotective effects of meldonium and trimetazidine in the model of L-NAME-induced endothelial dysfunction in experiment. Kurskiy nauchno-prakticheskiy vestnik. Chelovek i ego zdorov’e. 2010; 32: 5–10 (In Russ.)].

  12. Zhu Y., Zhang G., Zhao J. et al. Efficacy and safety of mildronate for acute ischemic stroke: a randomized, double-blind, active-controlled phase II multicenter trial. Clin Drug Investig. 2013; 33(10): 755–60. doi: 10.1007/s40261-013-0121-x.

  13. Котов С.В., Исакова Е.В., Волченкова Т.В. с соавт. Эффективность применения мельдония в остром периоде ишемического инсульта. Альманах клинической медицины. 2015; 39: 75–80. [Kotov S.V., Isakova E.V., Volchenkova T.V. et al. Efficacy of meldonium in acute period of ischemic stroke. Al'manakh klinicheskoy meditsiny. 2015; 39: 75–80 (In Russ.)]. doi: https://doi.org/10.18786/2072-0505-2015-39-75-81.

  14. Бурчинский С.Г. Стратегия нейрометаболической фармакотерапии у пациентов с артериальной гипертензией. Артериальная гипертензия. 2015; 6: 65–69. [Burchynskyi S.H. Strategy of neurometabolic pharmacotherapy in patients with hypertension. Arterial'naya gipertenziya. 2015; 6: 65–69 (In Russ.)].

  15. Недогода С.В., Стаценко М.Е., Туркина С.В. с соавт. Влияние терапии милдронатом на когнитивные функции у больных пожилого возраста с артериальной гипертензией. Кардиоваскулярная терапия и профилактика. 2012; 5: 33–38. [Nedogoda S.V., Statsenko M.E., Turkina S.V. Mildronate effects on cognitive function in elderly patients with arterial hypertension. Kardiovaskulyarnaya terapiya i profilaktika. 2012; 5: 33–38 (In Russ.)]. doi: https://doi.org/10.15829/1728-8800-2012-5-33-38.


About the Autors

Tatyana S. Heylo, ophthalmologist, Chief physician of Therapeutic Ophthalmology Center LLC. Address: 117218, Moscow, 18/2 Krzhizhanovskogo Str. Tel.: +7 (985) 769-73-50. E-mail: cto96@mail.ru. ORCID: https://orcid.org/0000-0002-8374-2645.
Julia A. Danilogorskaya, PhD, assistant of the Department of hospital therapy No.1 of N.V. Sklifosovsky Institute of clinical medicine of I.M. Sechenov First Moscow State Medical University (Sechenov University) of the Ministry of Healthcare of Russia. Address: 119021, Moscow, 11/2 Rossolimo Str. Tel.: +7 (916) 612-98-14. E-mail: julia_dan@mail.ru. ORCID: https://orcid.org/0000-0002-4994-8500.
Georgy B. Nazarenko, PhD, ophthalmologist of Therapeutic Ophthalmology Center LLC. Address: 117218, Moscow, 18/2 Krzhizhanovskogo Str. Tel.: +7 (499) 125-13-77. E-mail: cto96@mail.ru. ORCID: https://orcid.org/0000-0003-3567-821X.
Anatoly I. Martynov, MD, Academician of the Russian Academy of Sciences professor, professor of the Department of hospital therapy No. 1 of A.I. Yevdokimov Moscow State Medical and Dental University of the Ministry of Healthcare of Russia, president of RSMSIM. Address: 127473, Moscow, 20/1 Delegatskaya Str. Tel.: +7 (495) 609-67-00. E-mail: msmsu@msmsu.ru


Similar Articles

Back to Content

Бионика Медиа